Investigation of iodine dose effect on aortic and liver enhancement in abdominal CT and on coronary artery enhancement in cardiac CT in daily medical practice
Not Applicable
- Conditions
- hepatocellular carcinoma coronary infarction
- Registration Number
- JPRN-UMIN000008219
- Lead Sponsor
- Kumamoto University, Department of Radiology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2800
Inclusion Criteria
Not provided
Exclusion Criteria
(Exclusion criteria both abdominal and coronary CT) (1) With a past history of anaphylaxis to iodine and iodined contrast media (2) Serious thyroid disease (3) Women during pregnancy or lactation (4) eGFR less than 45mL/min (5) Patient who the doctor in charge judges are ineligible for the study (Exclusion criteria in the case of abdominal CT) (6) Those who underwent liver invasive therapy(ope/RFA/TAE etc.) within 3 months (Exclusion criteria in the case of coronary CT) (7) Severe cardiac arrest (8) Severe valve disease (9) Patient who underwent CABG surgery
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1) Correlation between the contrast enhancement of the sites below and the dose of iodine according to various body size-related indices, such as sex, height, weight, lean body weight (LBW), body surface area (BSA) and body mass index (BMI), Abdominal CT Aortic enhancement in arterial phase Liver parenchyma enhancement in portal venous phase Coronary CT CT value at the left main trunk and right coronary artery after administration of Iopamiron (2) Correlation between good-enhancement and factors affecting the CT enhancement (Definition of good-enhancement) Abdominal CT Aortic enhancement in arterial phase is 280 HU or more Liver parenchyma enhancement in portal venous phase is 50 HU or more Coronary CT CT value of the coronary artery (LMT, RCA) after administration of Iopamiron is 325 HU or more
- Secondary Outcome Measures
Name Time Method Correlation between the contrast enhancement (HU) and visual assessment Correlation between the contrast enhancement of liver(HU) and liver function Adverse effects